Lung Function, Coronary Artery Disease, and Mortality in HIV

Divay Chandra¹, Aman Gupta¹, Meghan Fitzpatrick¹, Sabina A. Haberlen², Maniraj Neupane¹, Joseph K. Leader³, Lawrence A. Kingsley⁴, Eric Kleerup⁵, Matthew J. Budoff⁶, Mallory Witt⁶, Frank C. Sciurba¹, Wendy S. Post^{2,7}, and Alison Morris¹

¹Department of Medicine, ³Department of Radiology, and ⁴Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania; ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; ⁵Department of Medicine, University of California at Los Angeles, Los Angeles, California; ⁶Los Angeles Biomedical Research Institute at Harbor-UCLA, Los Angeles, California; and ⁷Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland

Abstract

Rationale: Impaired lung function is a potent independent predictor of coronary artery disease (CAD) in individuals without human immunodeficiency virus (HIV) infection; however, the relationship between lung function and CAD in HIV remains undefined.

Objectives: To examine the relationship between lung function, CAD, mortality, and circulating biomarkers in HIV.

Methods: Spirometry, diffusing capacity of the lung for carbon monoxide (DL_{CO}), emphysema, coronary artery calcium, mortality, cause of death, and biomarkers were examined in HIV-infected and uninfected individuals enrolled in a cohort study at the University of Pittsburgh. Results were then validated in the Multicenter AIDS Cohort Study (MACS) cohort.

Results: We examined data on 234 participants in the Pittsburgh cohort. The mean $\pm$ standard deviation age was 49.5 ± 10.2 years old, 82.1% were male, and 67.5% were ever smokers. Among the 177

of 234 individuals with HIV infection, lower DL_{CO} (not forced expiratory volume in 1 second or emphysema) was independently associated with greater coronary artery calcium (odds ratio, 1.43 per 10% lower DL_{CO} ; 95% confidence interval, 1.14–1.81). HIV-infected individuals with both reduced DL_{CO} and coronary artery calcium had a much higher mortality than those with either low DL_{CO} or coronary calcium alone or with neither condition. Endothelin-1, a circulating biomarker of endothelial dysfunction, was associated with both lower DL_{CO} and greater coronary artery calcium in those with HIV infection. Results were reproducible in 144 individuals enrolled in the MACS cohort; intercellular adhesion molecule 1 was the biomarker of endothelial dysfunction assessed in the MACS cohort.

Conclusions: Impaired DL_{CO} and CAD were associated with each other and with higher mortality in individuals with HIV infection.

Keywords: HIV; coronary artery disease; mortality; endothelial dysfunction

(Received in original form July 11, 2018; accepted in final form March 13, 2019)

Supported by National Institutes of Health grants 1K23HL126912 (D.C.), K24HL123342 (A.M.), R01HL090339 (A.M.), U01-AI35042, U01-AI35039, U01-AI35040, U01-AI35041, UM1-AI35043, R01HL095129 (W.S.P.), and UL1-TR001079, as well as by the Samuel and Emma Winters Foundation (D.C.).

Author Contributions: D.C. conceptualized the study, performed and interpreted the analysis, and wrote the manuscript. A.G. assisted with assessment of coronary artery calcium scores and cause of death. M.F. assisted with data collection, analysis, and manuscript writing. S.A.H. assisted with data analysis. M.N. assisted with data collection. J.K.L. assisted with acquisition and interpretation of computed tomographic scans of the chest. M.J.B. assisted with coronary artery calcium scoring. F.C.S. assisted with conceptualizing the study. L.A.K., E.K., M.W., W.S.P., and A.M. established the cohorts and supervised data collection; and A.M. assisted with interpretation of data and manuscript preparation.

Correspondence and requests for reprints should be addressed to Divay Chandra, M.D., M.Sc., Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, NW628-UPMC Montefiore, 3459 Fifth Avenue, Pittsburgh, PA 15213. E-mail: dic15@pitt.edu.

This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org.

Ann Am Thorac Soc Vol 16, No 6, pp 687–697, Jun 2019

Copyright © 2019 by the American Thoracic Society

DOI: 10.1513/AnnalsATS.201807-460OC

Internet address: www.atsjournals.org

Coronary artery disease (CAD) is among the top five causes of death in persons with human immunodeficiency virus (HIV) infection, and its prevalence

is increasing as these individuals live longer with modern antiretroviral therapy (ART) (1–3). Nonetheless, understanding of the determinants and

risk factors for CAD in HIV remains incomplete.

In those without HIV infection, expiratory airflow limitation is a potent

independent predictor of CAD (4–6). For example, reduced forced expiratory volume in 1 second (FEV₁) was associated with a 77% increase in cardiovascular mortality compared with normal FEV₁ independent of smoking and other shared risk factors (pooled risk ratio, 1.77; 95% confidence interval [CI], 1.56–1.97) in a meta-analysis that included 83,330 individuals (7). Also, one-fourth of the attributable risk for mortality in ischemic heart disease was due to reduced FEV₁ in the Renfrew and Paisley community-based prospective cohort study (8). The findings of these studies have prompted greater awareness regarding the high morbidity and mortality due to CAD in those with chronic obstructive pulmonary disease (COPD) (9), efforts to incorporate FEV₁ into CAD risk stratification (10), and investigation into shared mechanisms between lung and coronary vascular injury (4). The latter has provided insight into the pathogenesis of both lung disease and atherosclerosis by novel inflammatory pathways as well as endothelial dysfunction (11, 12).

In contrast, despite the rising prevalence of lung disease and CAD with modern ART, it remains unclear if lung function and CAD are associated with each other in the HIV-infected population. On the one hand, there are differences in the epidemiology and pathogenesis of lung disease and CAD in individuals with versus without HIV infection (13–15). For example, COPD may occur at a younger age than in those without HIV infection and is associated with the degree of immunodeficiency (14, 16–19). Also, impaired diffusing capacity of the lung for carbon monoxide (DL_{CO}) is a more common lung function abnormality than airflow obstruction in those with HIV infection (20). Similarly, atherosclerosis occurs at an earlier age, and HIV Tat, gp120, and Nef proteins may play a unique role in its pathogenesis, unlike in those without HIV (21, 22). Despite these differences, an association between lung function and CAD in HIV is plausible because immune dysregulation and endothelial dysfunction occur in individuals with HIV infection similarly to uninfected individuals. Identification of such an association could have multiple implications, including potential inclusion of lung function in CAD risk prediction models in HIV and identification of shared mechanisms that may be targeted with novel multisystem

therapies to simultaneously mitigate lung and atherosclerotic vascular injury in HIV.

In the present study, we examined the relationship between lung function and CAD and how such a relationship may be associated with mortality and with a panel of circulating biomarkers in a cohort of individuals with and without HIV infection at the University of Pittsburgh. To determine if the results were reproducible, we examined data from a second multicenter cohort, despite the use of different methodologies in the second cohort (the Multicenter AIDS Cohort Study [MACS]). We hypothesized that impaired lung function and CAD would be associated with each other and with increased mortality in individuals with HIV.

Methods

Study Cohort

Enrollment criteria for the University of Pittsburgh and MACS cohorts have been described in detail previously (23, 24). In brief, the Pittsburgh cohort recruited men and women with and without HIV from outpatient clinics who were free of acute respiratory symptoms in the prior 4 weeks, whereas the MACS enrolled homosexual and bisexual men older than 18 years of age and without clinical acquired immunodeficiency syndrome at enrollment at four metropolitan centers in the United States. MACS participants who had been enrolled in both the pulmonary and cardiovascular substudies at Pittsburgh and Los Angeles MACS sites were included in the current analysis. If a participant was enrolled in both the Pittsburgh cohort and the MACS cohort, the individual was analyzed as part of the MACS cohort to maximize sample size in the MACS dataset. Both studies were approved by the institutional review boards at all participating sites, and written informed consent was obtained from each participant.

Coronary Artery Calcium

In the Pittsburgh cohort, coronary artery calcium (CAC) was measured using non-EKG-gated noncontrast thoracic computed tomographic (CT) scans by Weston score (25), whereas in the MACS cohort, it was assessed using electrocardiogram (EKG)-gated cardiac noncontrast CT scans by Agatston score (26). We have previously validated the Weston score as an excellent

surrogate for the Agatston score in individuals with and without HIV infection who were enrolled in the Pittsburgh and MACS cohorts (27), as have other investigators using data from other cohorts (25, 28, 29). Summed for the four coronary arteries, the total Weston score increases from 0 to 12 with increasing CAC. The Weston score was subcategorized using previously validated thresholds (i.e., none = 0; mild = 1, 2; moderate = 3–7; and severe = 8–12) (25, 27). Agatston scores were calculated using the area density method as described previously (26) and divided into four categories because of their skewed distribution per convention (i.e., none = 0; mild = 1–100; moderate = 101–400; and severe = >400) (30–32). Further details regarding CAC scoring are included in the online supplement.

The clinical interpretation of CAC scores has been discussed in detail previously in the general population (33), although data in individuals with HIV infection is not available, to our knowledge. A score of 0 is associated with a very low risk of future CAD events, and the risk for future CAD events increases with greater concentrations of CAC.

Lung Function, DL_{CO}, and Emphysema

In both cohorts, post-bronchodilator spirometry and DL_{CO} were assessed per American Thoracic Society guidelines (34) (*see* online supplement for details). DL_{CO} was defined as normal if it was greater than 80% of predicted in both cohorts.

Emphysema was assessed using density mask analysis of chest CT images as described previously (23). Two commonly used thresholds for quantifying emphysema (i.e., voxels depicting the lung with a Hounsfield unit [HU] value less than −950 [percentage low-attenuation area {LAA%} −950] or less than −910 [LAA% −910]) were used (35).

In the Pittsburgh cohort, pulmonary function tests and chest CT scanning were performed during the same study visit. In MACS participants, the median gap between pulmonary function and CAC assessments was 190 days (interquartile range [IQR], 102–400 d).

Cardiovascular Risk Factors

Established cardiovascular risk factors were assessed in both cohorts (*see* online supplement for details).

HIV Status

In both cohorts, HIV serostatus was defined during the same visit at which the CT scan was obtained. CD4 cell count, HIV viral level, and use of combination ART were assessed in individuals with HIV infection in both cohorts as described previously (23, 24).

Biomarkers

In the Pittsburgh cohort, concentrations of circulating markers of inflammation (interleukin [IL]-6 and IL-8), monocyte activation (sCD163 and sCD14), activation of coagulation and fibrinolytic systems (D-dimer), acute-phase response (high-sensitivity C-reactive protein), and endothelial dysfunction (endothelin-1) were measured by enzyme-linked immunosorbent assay or Luminex assay with samples collected during the same visit at which CT scanning and pulmonary function testing were performed, as described previously (36).

In the MACS cohort, levels of circulating biomarkers of systemic inflammation (IL-6), monocyte activation (sCD163 and sCD14), activation of coagulation and fibrinolytic systems (D-dimer), acute-phase response (fibrinogen and high-sensitivity C-reactive protein), tumor necrosis factor-mediated immune cell activation (soluble tumor necrosis factor- α receptor I [sTNF α RI] and receptor II [sTNF α RII]), and endothelial dysfunction (intercellular adhesion molecule 1 [ICAM-1]) were measured during the same visit that the CT scan was obtained, as described previously (37, 38).

Survival and Cause of Death

Survival in both cohorts was assessed via the Social Security Death Index and the National Death Index, supplemented by additional sources of information, such as physician or family report, obituaries, and medical record review. The methodology for determination of cause of death is described in the online supplement.

Statistical Analyses

Baseline characteristics were compared across severity of CAC. The association between lung function (predictor/independent variable) and CAC score (none/mild/moderate/severe as the outcome/dependent variable) was examined using ordinal logistic regression models. The

proportional odds assumption was tested using the Brant test. To further ensure that results were not dependent on the use of ordinal regression models, analyses were repeated with presence/absence of any CAC as the outcome variable. Because calcium scores have skewed distributions with many zero values, transformations such as logarithms or square roots do not normalize their distributions and were not attempted. Established cardiovascular risk factors as well as lung function variables were adjusted for as confounders. It was specified *a priori* that all models would be stratified by the presence or absence of HIV infection. Because the MACS cohort included data from two centers, we also examined the impact of adjusting for study site.

Kaplan-Meier survival curves were plotted to examine survival, whereas Cox proportional hazards models were used to estimate hazard ratios (HRs) adjusted for covariates. Survival time was ascertained from the date of the CT scan.

The chi-square test was used to compare categorical variables, and the Kruskal-Wallis test was used for continuous variables. *Post hoc* power analyses and multiple imputation for missing data were performed (see online supplement for details). Analyses were performed using Stata MP version 14.1 (StataCorp). A two-tailed *P* value less than 0.05 was defined as statistically significant. Adjustment for multiple comparisons by estimation of false discovery rates was not considered necessary, because the number of predictors for a given outcome was modest (e.g., various measures of pulmonary function as predictors of CAC and six or seven biomarkers as predictors of DL_{CO} and CAC).

Results

Participant Characteristics, Lung Function, and CAC in the Pittsburgh Cohort

We included 234 participants after excluding 109 who were enrolled in both cohorts, 48 with missing blood pressure measurements, 27 with missing emphysema assessment, 5 without DL_{CO} assessment, and 13 with missing information for various other variables. The 109 individuals enrolled in both the Pittsburgh and MACS cohorts were included in the MACS dataset rather than in the Pittsburgh cohort to preserve statistical power in the MACS dataset

(*n* = 161, including the 109 coenrolled). Included participants tended to be younger (49.6 ± 10.2 vs. 55.2 ± 8.8 yr), were more frequently current smokers (43.2% vs. 28.6%), had lower DL_{CO} ($71.8 \pm 14.7\%$ vs. $86.8 \pm 18.0\%$ predicted), and were more frequently HIV infected (75.6% vs. 56.8%) than excluded participants.

Participants in the Pittsburgh cohort were 49.6 ± 10.2 years of age, 82.1% male, 59.8% non-Hispanic white, and 67.5% ever smokers. One hundred seventy-seven had HIV infection (75.6%) and had mostly preserved CD4 counts (median, 602 cells/ μ L; IQR, 390–811 cells/ μ L) and low HIV viral levels (undetectable in 71.2%). Expiratory airflow limitation was on average mild, although individuals with a wide range of severity were enrolled (post-bronchodilator FEV₁, 93.2 ± 18.3 ; range, 34.4–139.4%; FEV₁/forced vital capacity [FVC], 0.80 ± 0.08 ; range, 0.45–0.97; 15.4% met the spirometric definition of airflow limitation [i.e., FEV₁/FVC < 0.7]). Similarly, DL_{CO} was mildly impaired on average ($71.8 \pm 14.7\%$ predicted); however, individuals with a wide range of DL_{CO} values were enrolled (range, 20.8–112.8%).

Fifty-six percent of participants had no CAC, whereas 23.9% had mild, 7.7% had moderate, and 12.4% had severe CAC (Table 1). The median CAC score was 0 (IQR, 0–3) in all comers, 0 (IQR, 0–6) in those without HIV, and 0 (IQR, 0–3) in those with HIV infection (*P* = 0.42 comparing those with and without HIV infection). DL_{CO} and FEV₁/FVC ratio both decreased significantly with increasing CAC in unadjusted analyses (Table 1) per 10% decrease in DL_{CO} percent predicted (odds ratio [OR], 1.25; 95% CI, 1.05–1.48) and per 10% lower FEV₁/FVC (OR, 1.40; 95% CI, 1.06–1.85). In contrast, we did not detect an association between either lower FEV₁ percent predicted or emphysema measures with CAC (Table 1) per 10% decrease in FEV₁ percent predicted (OR, 1.13; 95% CI, 0.98–1.30) and per 10% greater LAA% – 910 HU (OR, 1.01; 95% CI, 0.98–1.04). We did not detect an association between CAC and HIV serostatus, CD4 count, viral load, or use of ART. Expected associations between CAC and older age, male sex, white race, and higher systolic blood pressure were present (Table 1).

Participant Characteristics, Lung Function, and CAC in the MACS Cohort

In the MACS cohort, 161 participants underwent measurement of lung function

and CAC. Four were excluded because of missing DL_{CO} values, one was excluded because of missing CAC score, and 12 were excluded because of missing data for other variables. The remaining 144 participants were 54.3 ± 7.0 years old, all men, 82.1% non-Hispanic white, and 77.6% ever smokers. Eighty-one (56.2%) had HIV infection, with mostly preserved CD4 counts (median, 644 cells/μl; IQR, 399 cells/μl) and low HIV viral levels (undetectable in 77.4%). Similarly to the Pittsburgh cohort, airflow limitation and DL_{CO} were minimally impaired, on average, but with a wide range of severity (FEV₁, 101.4 ± 18.3; range, 43.3–132.9% predicted; FEV₁/FVC, 0.80 ± 0.08; range, 0.48–0.90; with 12.5% meeting the spirometric definition of airflow limitation [i.e., FEV₁/FVC < 0.7; DL_{CO}, 85.0 ± 21.1; range, 27.4–138.3% predicted).

No CAC was present in 43.1% of participants, whereas 25.0% had mild, 23.6%

had moderate, and 8.3% had severe CAC (Table 1). The median CAC score was 12.5 (IQR, 0–139.9) in all comers, 14.8 (IQR, 0–184.2) in those without HIV, and 9.1 (IQR, 0–131.23) in those with HIV infection (*P* = 0.90 comparing those with and without HIV infection). Findings in the Pittsburgh cohort were also present in MACS (1): Reduced DL_{CO} and FEV₁/FVC values were associated with higher CAC scores per 10% less DL_{CO} percent predicted (OR, 1.28; 95% CI, 1.07–1.51) and per 10% lower FEV₁/FVC (OR, 1.47; 95% CI, 1.04–2.01) (2). Neither FEV₁ per 10% less FEV₁ percent predicted (OR, 1.11; 95% CI, 0.93–1.34) nor emphysema per 10% higher LAA% –910 HU (OR, 0.90; 95% CI, 0.72–1.15) was associated with CAD (3), HIV infection (OR, 1.13; 95% CI, 0.62–2.08), CD4 count per 100/ml lower CD4 count (OR, 0.98; 95% CI, 0.93–1.11; *n* = 81), viral load per 1,000/ml higher viral load (OR, 0.98; 95% CI, 0.95–1.02; *n* = 81), and use of ART (OR, 2.03; 95% CI,

0.62–6.67; *n* = 81) were not associated with CAC scores (Table 2).

Multivariate Analyses

Because DL_{CO} demonstrated a statistically significant association with CAC in both cohorts, unlike FEV₁ percent predicted and measures of emphysema severity, it was further examined in adjusted models. Also, impairment in DL_{CO} is the most common lung function abnormality in individuals with HIV infection and is associated with inflammation and pulmonary vascular disease (20, 39).

Participant characteristics stratified by DL_{CO} are summarized in Tables E1 and E2 in the online supplement. In the Pittsburgh cohort, each 10% lower DL_{CO} was associated with a 43% increase in the odds of being in one higher category of severity of CAC score (OR, 1.43; 95% CI, 1.14–1.81) (Figure 1) after adjustment for age, sex, race, pack-years of smoking, systolic blood pressure,

Table 1. Characteristics of the participants in the University of Pittsburgh cohort, stratified by severity of coronary artery calcium

	None	Mild	Moderate	Severe
<i>n</i> (%)	131 (56.0)	56 (23.9)	18 (7.7)	29 (12.4)
Age, yr	45.7 (9.7)	51.9 (7.9)	55.8 (9.6)	58.6 (8.2)
Male sex, <i>n</i> (%)	98 (74.8)	50 (89.3)	18 (100.0)	26 (89.7)
Race				
Non-Hispanic white, <i>n</i> (%)	62 (47.3)	40 (71.4)	15 (83.3)	23 (79.3)
Non-Hispanic black, <i>n</i> (%)	69 (52.7)	16 (28.6)	3 (16.7)	6 (20.7)
Blood pressure				
Systolic, mm Hg	125.3 (15.7)	130.4 (14.8)	128.0 (17.2)	131.6 (14.6)
Diastolic, mm Hg	76.7 (10.8)	79.8 (8.8)	81.1 (6.6)	77.7 (10.6)
Diabetes mellitus, <i>n</i> (%)	6 (4.6)	0 (0.0)	1 (5.6)	4 (13.8)
BMI, kg/m ²	28.2 (6.3)	27.1 (6.2)	26.0 (4.9)	28.6 (4.9)
Smoking status				
Never smoker, <i>n</i> (%)	36 (27.5)	23 (41.1)	8 (44.4)	9 (31.0)
Prior smoker, <i>n</i> (%)	36 (27.5)	11 (19.6)	3 (16.7)	7 (24.1)
Current smoker, <i>n</i> (%)	59 (45.0)	22 (39.3)	7 (38.9)	13 (44.8)
Pack-years of smoking (<i>n</i> = 158)*	14.3 (15.7)	17.2 (22.3)	16.1 (17.3)	21.6 (24.8)
FEV ₁ , % predicted	96.0 (18.3)	93.1 (17.0)	90.9 (18.9)	90.6 (20.3)
FEV ₁ /FVC	0.79 (0.07)	0.77 (0.09)	0.75 (0.11)	0.76 (0.10)
DL _{CO} , % predicted	73.8 (14.5)	71.0 (14.8)	64.8 (15.0)	68.5 (14.3)
LAA% –950 HU	1.7 (4.1)	2.0 (3.2)	1.4 (1.1)	1.6 (1.5)
LAA% –910 HU	9.5 (10.0)	11.7 (9.7)	10.0 (8.3)	10.4 (7.5)
HIV infected, <i>n</i> (%)	100 (76.3)	47 (83.9)	11 (61.1)	19 (65.5)
CD4 count, hundreds/ml (<i>n</i> = 177) ^{†‡}	6.2 (3.9–8.6)	6.0 (4.6–7.7)	4.1 (2.1–6.9)	6.2 (3.5–7.2)
Viral load undetectable, % (<i>n</i> = 177) [†]	69.0	70.2	63.6	89.5
Viral load, thousands/ml (<i>n</i> = 51) ^{‡§}	4.6 (0.3–37.4)	0.3 (0.09–1.9)	0.6 (0.3–8.1)	16.5 (0.7–32.2)
ART, <i>n</i> (%) (<i>n</i> = 177) [†]	88 (67.20)	37 (66.1)	10 (55.6)	19 (65.5)

Definition of abbreviations: ART = antiretroviral therapy; BMI = body mass index; DL_{CO} = diffusing capacity of the lung for carbon monoxide; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; HIV = human immunodeficiency virus; LAA% –910 HU = percentage low-attenuation area at values less than –910 Hounsfield units; LAA% –950 HU = percentage low-attenuation area at values less than –950 Hounsfield units; SD = standard deviation. Severity of coronary artery calcium is scored for the Weston score as follows: none = 0; mild = 1–2; moderate = 3–7; and severe = 8–12. Continuous variables are summarized as mean ± SD, unless noted otherwise.

*Pack-years are reported only for the 158 current and prior smokers.

[†]CD4 count, viral load undetectable, and ART use are reported only for the 177 HIV-seropositive individuals.

[‡]Reported as median (interquartile range) because of the highly skewed distribution.

[§]Reported in the 51 of 177 HIV-positive patients with detectable viral load.

Table 2. Characteristics of the participants in the Multicenter AIDS Cohort Study cohort, stratified by severity of coronary artery calcium

	None	Mild	Moderate	Severe
<i>n</i> (%)	62 (43.1)	36 (25.0)	34 (23.6)	12 (8.3)
Age, yr	51.5 (6.6)	56.7 (6.9)	56.6 (6.5)	58.9 (4.9)
Race, <i>n</i> (%)				
Non-Hispanic white	42 (67.7)	31 (86.1)	29 (85.3)	12 (100.0)
Non-Hispanic black	15 (24.2)	5 (13.9)	5 (14.7)	0 (0.0)
Other	5 (8.1)	0 (0.0)	0 (0.0)	0 (0.0)
BMI, kg/m ²	26.3 (4.2)	27.1 (4.6)	28.2 (5.8)	28.3 (6.9)
Smoking status				
Pack-years of smoking, <i>n</i> (<i>n</i> = 95)*	10.6 (15.2)	13.5 (19.0)	23.6 (23.6)	21.1 (18.7)
Ever smoker, <i>n</i> (%)	44 (71.0)	28 (77.8)	28 (84.8)	11 (91.7)
Diabetes mellitus, <i>n</i> (%)	4 (6.6)	0 (0.0)	7 (23.3)	1 (10.0)
Hypertension, <i>n</i> (%)	21 (36.8)	20 (58.8)	20 (66.7)	9 (75.0)
Hyperlipidemia, <i>n</i> (%)	47 (75.8)	29 (80.6)	28 (87.5)	12 (100.0)
FEV ₁ , % predicted	99.8 (15.1)	100.3 (16.5)	97.6 (16.9)	92.2 (26.6)
FEV ₁ /FVC	0.8 (0.1)	0.8 (0.1)	0.8 (0.1)	0.8 (0.1)
DL _{CO} , % predicted	89.7 (19.6)	86.6 (14.7)	80.1 (19.2)	78.0 (21.2)
LAA% −950 HU	18.8 (15.7)	17.0 (12.1)	16.1 (11.6)	18.0 (10.9)
LAA% −910 HU	3.3 (6.2)	2.3 (2.3)	2.9 (4.4)	2.6 (2.3)
HIV seropositive, <i>n</i> (%)	34 (54.8)	21 (58.3)	17 (50.0)	9 (75.0)
CD4 count, hundreds/ml (<i>n</i> = 81) ^{†‡}	6.7 (3.9–8.5)	5.8 (4.8–7.4)	6.4 (4.3–8.5)	7.0 (5.9–9.0)
Viral load undetectable, % (<i>n</i> = 81) [†]	64.7	90.5	94.1	66.7
Viral load, thousands/ml (<i>n</i> = 21) ^{†§}	1.2 (0.6–17.4)	0.05 (0.02–0.08)	40.4 (40.4–40.4)	3.7 (0.8–35.1)
Duration of ART, yr (<i>n</i> = 81) [†]	8.2 (11.2)	11.1 (7.4)	8.5 (5.3)	12.9 (5.8)

Definition of abbreviations: ART = antiretroviral therapy; BMI = body mass index; DL_{CO} = diffusing capacity of the lung for carbon monoxide; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; HIV = human immunodeficiency virus; LAA% −910 HU = percentage low-attenuation area at values less than −910 Hounsfield units; LAA% −950 HU = percentage low-attenuation area at values less than −950 Hounsfield units; SD = standard deviation. Severity of coronary artery calcium is scored for the Agatston score as follows: none = 0; mild = 1–100; moderate = 101–400; and severe = >401.

Continuous variables are summarized as mean ± SD, unless noted otherwise.

*Pack-years are reported only for the 95 current and prior smokers.

[†]CD4 count, viral load, and ART use are reported only for the 81 HIV-seropositive individuals.

[‡]Reported as median (interquartile range) because of the highly skewed distribution.

[§]Reported in the 21 of 81 HIV-positive patients with detectable viral load.

diabetes mellitus, LAA% −910 HU, and FEV₁ percent predicted. The association was statistically significant only in those with HIV infection, although the sample size (and hence statistical power) was lower in the HIV-uninfected subgroup and *P* value for interaction due to HIV status was nonsignificant (*P* = 0.24) (Figure 1).

The presence and magnitude of this association was reproduced in the MACS cohort: Each 10% lower DL_{CO} percent predicted level was associated with a 48% increase in the odds of being in one higher category of severity of CAC score (OR, 1.44; 95% CI, 1.12–1.90) (Figure 1) after adjusting for age, race, pack-years of smoking, hypertension, diabetes, hyperlipidemia, LAA% −910 HU, and FEV₁ percent predicted. Similarly to the Pittsburgh cohort, the fully adjusted association appeared stronger in those with HIV infection, although the sample size (and hence statistical power) was lower in the HIV-uninfected subgroup and the *P* value for interaction due to HIV

status was nonsignificant (*P* = 0.46)

(Figure 1).

When analyses were repeated with presence or absence of CAC as the outcome variable, the results were unchanged (*see* online supplement). Also, the Brant test for the proportional odds assumption generated a nonsignificant *P* value, suggesting that the proportional odds assumption had not been violated (*P* = 0.46 in the Pittsburgh cohort and *P* = 0.82 in MACS data). Finally, adjustment for study site in the MACS cohort did not impact the results, and study site was not a significant predictor of CAC score (*P* = 0.98) (*see* online supplement)

Impaired DL_{CO}, CAC, and Mortality

Because the association between DL_{CO} and CAC was significant only in those with HIV infection in both cohorts (Figure 2), further examination of this association was performed in the participants with HIV infection in both cohorts. To understand the clinical significance of the association between reduced DL_{CO} and increased CAC

in the HIV-infected cohort, we examined mortality in those with both reduced DL_{CO} and presence of calcium compared with those with only reduced DL_{CO}, only presence of calcium, and absence of both low DL_{CO} and calcium (Tables E3 and E4). Those with a low DL_{CO} and presence of CAC had significantly higher mortality than those in either of the other subgroups (Figure 2).

In the Pittsburgh cohort, over a median follow-up of 5.9 years (IQR, 5.2–7.1 yr), mortality was 21.6% in those with low DL_{CO} and presence of calcium (HR, 6.3; 95% CI, 1.3–29.7), 12.5% in those with normal DL_{CO} and presence of calcium (HR, 3.3; 95% CI, 0.6–17.4), 10.4% in those with low DL_{CO} and no calcium (HR, 2.6; 95% CI, 0.5–13.3), and 3.8% in those with normal DL_{CO} and no calcium (reference group). Adjustment for age, sex, race, pack-years of smoking, CD4 count, and viral load had minimal impact on these findings. Specifically, those with low DL_{CO} and presence of calcium had increased mortality compared with those with normal DL_{CO} and no calcium (adjusted HR, 6.7;

Figure 1. The unadjusted and adjusted odds ratios for the associations between diffusing capacity of the lung for carbon monoxide (DL_{CO}) and coronary artery calcium score among 234 participants in the Pittsburgh cohort and 144 participants in the Multicenter AIDS Cohort Study (MACS) cohort. The fully adjusted associations were further stratified by the presence or absence of human immunodeficiency virus (HIV) infection. *Variables adjusted for: age, sex, race, pack-years of smoking, systolic blood pressure, history of diabetes mellitus, LAA% -910 HU, and FEV_1 % predicted. †Variables adjusted for: age, race, pack-years of smoking, presence of hypertension, presence of diabetes, presence of hyperlipidemia, LAA% -950 HU, and FEV_1 % predicted. FEV_1 = forced expiratory volume in 1 second; LAA% -910 HU = percentage low-attenuation area at values less than -910 Hounsfield units; LAA% -950 HU = percentage low-attenuation area at values less than -950 Hounsfield units.

95% CI, 1.2–36.0), whereas there was no statistically significant difference in mortality in the other subgroups (normal DL_{CO} and presence of calcium, and low DL_{CO} and no calcium) compared with those with normal DL_{CO} and no calcium.

Results were similar in the MACS cohort: Mortality was 26.3% in those with low DL_{CO} and CAC compared with 10.7% in those with normal DL_{CO} and CAC, 0% in those with low DL_{CO} and no coronary calcium, and 0% in those with normal DL_{CO} and no coronary calcium ($P = 0.009$) over a median follow-up of 6.6 years (IQR, 5.5–7.1 yr).

Examination of the cause of death in the Pittsburgh cohort revealed that only one death was related to immunodeficiency (Table E5). Although the number of deaths was low, liver disease was a frequent cause of death in those with low DL_{CO} and CAC. Similarly, in the

MACS cohort, deaths occurred for various reasons unrelated to immunodeficiency (Table E6). Therefore, these data suggested that the presence of impaired DL_{CO} and CAC was associated with worse survival due to non-immunodeficiency-related causes.

Impaired DL_{CO} , CAC, and Biomarkers

Next, to gain insight into pathological processes associated with both DL_{CO} impairment and CAD, we sought biomarkers associated with both reduced DL_{CO} and increased CAC in individuals with HIV infection. In the Pittsburgh cohort, the only such biomarker was endothelin-1, a marker of endothelial dysfunction (Figure 3). Although endothelin-1 had not been assessed in MACS, the related biomarker of endothelial dysfunction, ICAM-1, showed the same associations with

decreasing DL_{CO} and increasing coronary calcium (Figure 3). Further details of the biomarker analyses are included in the online supplement.

Missing Data, Power, and Sample Size

Analyses performed to determine the impact of missing data did not suggest significant bias due to missing data (see online supplement). Power and sample size calculations suggested that in individuals without HIV, the ability to detect an association between DL_{CO} and CAC was limited by the small sample size (see online supplement and Figure E1). Therefore, the absence of an association between DL_{CO} and CAC in individuals without HIV infection in our analyses may have resulted from inadequate power rather than from the true absence of an association.

Figure 2. Kaplan-Meier survival curves stratified by presence/absence of coronary artery calcium and presence/absence of reduced diffusing capacity of the lung for carbon monoxide (DL_{CO}) among (A) 177 participants with human immunodeficiency virus (HIV) infection in the Pittsburgh cohort and (B) 81 participants with HIV infection in the Multicenter AIDS Cohort Study.

Discussion

We examined the association between lung function and CAD in individuals with and without HIV. Our results suggest that impaired DL_{CO} , rather than airflow limitation or emphysema, is independently associated with greater CAC in individuals with HIV infection. Furthermore, this

association appeared to be clinically meaningful because individuals with HIV infection with reduced DL_{CO} and presence of CAC were at increased risk of death compared with those with only DL_{CO} impairment, only coronary artery calcification, or neither. Biomarkers of endothelial dysfunction were associated with both impaired DL_{CO} and increased

CAC scores in the individuals with HIV infection. These results were reproducible in an unrelated cohort of individuals enrolled in a multicenter study.

In individuals without HIV, the association between impaired FEV_1 and CAD is well established (4, 7, 11). This association has led to increased awareness regarding the morbidity and mortality of

Figure 3. The diffusing capacity of the lung for carbon monoxide (DL_{CO}) percent predicted and coronary artery calcium score (median with interquartile range) in participants with human immunodeficiency virus infection, grouped by quartile of circulating endothelin-1 level in (A) the Pittsburgh cohort and by quartile of circulating intercellular adhesion molecule 1 (ICAM-1) level in (B) the Multicenter AIDS Cohort Study.

CAD in COPD, efforts to screen for CAD in those with COPD, and efforts to incorporate airflow limitation in CAD risk prediction models in COPD (9, 10). Also, a number of shared mechanisms for lung and coronary atherosclerosis have been identified, and it is now widely accepted that lung disease and CAD may be manifestations of shared underlying biological processes.

One such biological process is systemic endothelial dysfunction (40, 41). Endothelial dysfunction often refers to reduced bioavailability and impaired vasodilatory effects of endothelium-derived relaxing factors such as nitric oxide, prostacyclin, or endothelium-derived hyperpolarizing factors (42). Endothelial dysfunction in systemic arteries is a

precursor to atherosclerosis and has also been linked to pulmonary emphysema in those without HIV (41). Nonetheless, the role of endothelial dysfunction as a physiological abnormality linking lung disease and CAD in those without HIV infection remains controversial (4).

In individuals with HIV, impaired DL_{CO} rather than airflow limitation appeared to be associated with CAD in our cohorts. Possible explanations for this finding include the underlying pathophysiology of lung impairment and CAD being different in individuals with HIV than in the general population. As discussed above, COPD occurs at a younger age than in those without HIV infection and is associated with the degree of

immunodeficiency in individuals with HIV infection. Similarly, atherosclerosis occurs at an earlier age, and HIV-specific mechanisms and mediators (HIV Tat, gp120, Nef proteins) may play a unique role. Alternatively, this finding may be due to chance or may be related to inadequate power to detect an association between FEV₁ and CAC, despite adequate power to detect an association between DL_{CO} and CAC.

Only one prior study has examined the relationship between lung disease and CAD, to our knowledge (43). In this study, Agatston CAC scores and visual emphysema scores were assessed using EKG-gated cardiac CT scans. The presence of emphysema was associated with the

presence of CAC (OR, 1.34; 95% CI, 1.08–1.88; $P = 0.01$) independent of age, sex, smoking status, pack-years of smoking, visceral adiposity, and duration of HIV infection. Assessment of lung function, DL_{CO} , mortality, and biomarkers was not performed. Unlike the prior study, in our examination of the Pittsburgh and the MACS cohorts, quantitative assessments of emphysema were not associated with CAC scores. Therefore, it is possible that had spirometry and DL_{CO} been measured in the previous study, they would have been more closely associated with CAC than with emphysema. Nonetheless, as interest in assessment of CAC and emphysema using lung cancer screening CT scans continues to increase, it is likely that more data regarding a possible association between emphysema and CAC in HIV will become available in the future (44).

Multiple studies show that endothelial dysfunction occurs in individuals with HIV infection regardless of ART and is a risk factor for accelerated atherosclerosis (45–48). Our biomarker data suggest that endothelial dysfunction is associated not only with atherosclerosis but also with pulmonary vascular dysfunction as assessed by DL_{CO} . In a previous analysis of data from the Pittsburgh cohort, we reported that higher IL-6 and endothelin-1 were associated with lower FEV₁ percent predicted; higher sCD163 was associated with worse FEV₁/FVC; and higher IL-6, TNF- α , lipopolysaccharide, sCD163, IL-2 receptor, and endothelin-1 were associated with lower DL_{CO} . The present results suggest that among these biomarkers, endothelin-1 may be unique because it is also associated with CAD. Although the biomarker results are intriguing, they should be considered preliminary pending independent replication because different biomarkers were examined in the two cohorts.

Examination of the cause of death suggested that mortality was largely unrelated to immunodeficiency. The causes appeared variable with no obvious connection to CAD, impaired DL_{CO} , or endothelial dysfunction. Although the numbers are small, it is possible that death caused by liver disease was more frequent in those with low DL_{CO} , possibly because liver disease can be associated with impaired DL_{CO} .

To integrate the various findings of our analyses, we present a hypothetical

conceptual diagram (Figure 4). In this model, HIV infection induces pulmonary and systemic endothelial dysfunction. The resulting pulmonary endothelial injury propagates pulmonary vascular dysfunction manifesting as impaired DL_{CO} (46), whereas coronary endothelial dysfunction leads to coronary atherosclerosis manifesting as increased CAC score (47). Impairment of DL_{CO} and CAD, in turn, contributes to increased mortality. This model is hypothetical because we did not examine the causality or underlying mechanisms of the associations presented; however, it represents one possible framework for integration of the associations described in the present study.

Our findings may have multiple implications. First, addition of lung function to CAD risk prediction models may help improve the calibration and tendency of these models to underestimate CAD risk in HIV (49, 50). Furthermore, identification of shared mechanisms for lung disease and CAD in HIV may provide avenues to develop novel multisystem therapies. For example, statins are known to reduce endothelial dysfunction and CAD in HIV (51, 52). In a recent pilot study, we found that statin therapy also improves lung function, including DL_{CO} , in individuals with HIV infection and also decreases circulating endothelin-1 concentrations (53). Therefore, it is plausible that statins may be an effective multisystem therapy in HIV that can simultaneously reduce pulmonary disease and CAD by targeting the shared underlying mechanism of endothelial dysfunction.

The present study has limitations. First, CAC was assessed using non-EKG-gated

CT scans in the Pittsburgh cohort. However, this technique has been validated by multiple independent investigators (25, 27–29), and results were the same for CAC assessed by EKG-gated cardiac CT scans in the MACS cohort (Agatston scores). Although it is possible to perform Agatston scoring on the non-EKG-gated CT scans, this technique requires proprietary cardiac imaging software and specialized expertise, making it time and cost prohibitive for our study. Similarly, lipid panels and fasting blood glucose were not measured in the Pittsburgh cohort, but these were assessed in the MACS cohort, and the same independent associations between DL_{CO} and CAD were identified. Second, in the MACS cohort, emphysema assessment was performed using different CT scanners at the two centers. However, adjustment for study site did not alter our findings, suggesting that use of different CT equipment did not introduce significant bias in our results. Third, related but different biomarkers for endothelial dysfunction were assessed in the two cohorts. Also, we did not have data on pulmonary artery systolic pressure, right ventricular function, or interstitial abnormalities that can all impact DL_{CO} and mortality (54). Furthermore, owing to the methodological differences between the two cohorts, we decided not to merge the two datasets into one statistical analysis. Therefore, findings from the two cohorts stand alone and do not confound each other. Although differences in methodology between cohorts complicate the presentation and interpretation of data, replication of results in a second multicenter cohort that used different methods strengthens the validity of the results.

Figure 4. A hypothetical conceptual diagram based on the various associations identified in the present study. HIV = human immunodeficiency virus.

Finally, statistical power was limited for some comparisons, particularly in individuals without HIV infection, and multiple biomarkers were analyzed, raising the risk of false-negative and false-positive results, respectively.

In conclusion, we identified a novel independent association between impaired DL_{CO} and CAD in individuals with HIV infection. Pulmonary vascular and coronary vascular injury should be further investigated as potentially related processes that may be associated with markers of endothelial dysfunction and higher mortality in HIV. Future studies should also examine if addition of DL_{CO} improves CAD risk prediction models in HIV and explore shared mechanisms for lung and coronary vascular injury that may provide insight into the pathogenic mechanisms of lung and cardiovascular disease in HIV. ■

Author disclosures are available with the text of this article at www.atsjournals.org.

Acknowledgment: Data in this article were collected by the Multicenter AIDS Cohort Study

(MACS) with centers in Baltimore (U01-AI35042) at Johns Hopkins University Bloomberg School of Public Health: Joseph B. Margolick (principal investigator), Jay Bream, Todd Brown, Barbara Crain, Adrian Dobs, Michelle Estrella, W. David Hardy, Lisette Johnson-Hill, Sean Leng, Anne Monroe, Cynthia Munro, Michael W. Plankey, Wendy Post, Ned Sacktor, Jennifer Schrack, Chloe Thio; in Chicago (U01-AI35039) at Feinberg School of Medicine, Northwestern University, and Cook County Bureau of Health Services: Steven M. Wolinsky (principal investigator), John P. Phair, Sheila Badri, Dana Gabuzda, Frank J. Palella, Jr., Sudhir Penugonda, Susheel Reddy, Matthew Stephens, Linda Teplin; in Los Angeles (U01-AI35040) at University of California, UCLA Schools of Public Health and Medicine: Roger Detels (principal investigator), Otoniel Martinez-Maza (co-principal investigator), Aaron Aronow, Peter Anton, Robert Bolan, Elizabeth Breen, Anthony Butch, Shehnaz Hussain, Beth Jamieson, Eric N. Miller, John Oishi, Harry Vinters, Dorothy Wiley, Mallory Witt, Otto Yang, Stephen Young, Zuo Feng Zhang; in Pittsburgh (U01-AI35041) at University of Pittsburgh Graduate School of Public Health: Charles R. Rinaldo (principal investigator), Lawrence A. Kingsley (co-principal investigator), James T. Becker, Phalguni Gupta, Kenneth Ho, Susan Koletar, Jeremy J. Martinson, John W. Mellors, Anthony J. Silvestre, Ronald D. Stall; the data coordinating center (UM1-AI35043) at

Johns Hopkins University Bloomberg School of Public Health: Lisa P. Jacobson (principal investigator), Gypsyamber D'Souza (co-principal investigator), Alison, Abraham, Keri Althoff, Jennifer Deal, Priya Duggal, Sabina Haberlen, Eithne Keelagan, Alvaro Muñoz, Derek Ng, Eric C. Seaberg, Sol Su, Pamela Surkan; National Institute of Allergy and Infectious Diseases (NIAID): Robin E. Huebner; National Cancer Institute (NCI): Geraldina Dominguez. The MACS is funded primarily by the NIAID, with additional cofunding from the NCI, the National Institute on Drug Abuse, and the National Institute of Mental Health. Targeted supplemental funding for specific projects was also provided by the National Heart, Lung, and Blood Institute and the National Institute on Deafness and Communication Disorders. MACS data collection is also supported by UL1-TR001079 (Johns Hopkins University Institute for Clinical and Translational Research [ICTR]) from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the NIH, the Johns Hopkins ICTR, or NCATS. The MACS website is located at <http://aidscohortstudy.org/>.

References

- Boccard F, Cohen A. Immune activation and coronary atherosclerosis in HIV-infected women: where are we now, and where will we go next? *J Infect Dis* 2013;208:1729–1731.
- Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sørensen HT, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. *Clin Infect Dis* 2007;44:1625–1631.
- Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al.; D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *Lancet* 2014;384:241–248.
- Chandra D, Gupta A, Strollo PJ Jr, Fuhrman CR, Leader JK, Bon J, et al. Airflow limitation and endothelial dysfunction: unrelated and independent predictors of atherosclerosis. *Am J Respir Crit Care Med* 2016;194:38–47.
- Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. *Transl Res* 2013;162:237–251.
- Truelsen T, Prescott E, Lange P, Schnohr P, Boysen G. Lung function and risk of fatal and non-fatal stroke: the Copenhagen City Heart Study. *Int J Epidemiol* 2001;30:145–151.
- Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. *Chest* 2005;127:1952–1959.
- Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. *BMJ* 1996;313:711–715, discussion 715–716.
- Man SFP, Leipsic JA, Man JP, Sin DD. Is atherosclerotic heart disease in COPD a distinct phenotype? *Chest* 2011;140:569–571.
- Roversi S, Fabbri LM, Sin DD, Hawkins NM, Agustí A. Chronic obstructive pulmonary disease and cardiac diseases: an urgent need for integrated care. *Am J Respir Crit Care Med* 2016;194:1319–1336.
- Corbi G, Bianco A, Turchiarelli V, Cellurale M, Fatica F, Daniele A, et al. Potential mechanisms linking atherosclerosis and increased cardiovascular risk in COPD: focus on sirtuins. *Int J Mol Sci* 2013;14:12696–12713.
- King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. *Clin Transl Med* 2015;4:68.
- Leader JK, Crothers K, Huang L, King MA, Morris A, Thompson BW, et al. Risk factors associated with quantitative evidence of lung emphysema and fibrosis in an HIV-infected cohort. *J Acquir Immune Defic Syndr* 2016;71:420–427.
- Chand HS, Vazquez-Guillamet R, Royer C, Rudolph K, Mishra N, Singh SP, et al. Cigarette smoke and HIV synergistically affect lung pathology in cynomolgus macaques. *J Clin Invest* 2018;128:5428–5433.
- Verboeket SO, Wit FW, Kirk GD, Drummond MB, van Steenwijk RP, van Zoest RA, et al.; AGEHIV Study Group. Reduced forced vital capacity among human immunodeficiency virus-infected middle-aged individuals. *J Infect Dis* 2019;219:1274–1284.
- Morris A, George MP, Crothers K, Huang L, Lucht L, Kessinger C, et al.; Lung HIV Study. HIV and chronic obstructive pulmonary disease: is it worse and why? *Proc Am Thorac Soc* 2011;8:320–325.
- Risso K, Guillouet-de-Salvador F, Valerio L, Pugliese P, Naqvi A, Durant J, et al. COPD in HIV-infected patients: CD4 cell count highly correlated. *PLoS One* 2017;12:e0169359.
- Ronit A, Lundgren J, Afzal S, Benfield T, Roen A, Mocroft A, et al.; Copenhagen Co-morbidity in HIV infection (COCOMO) study group. Airflow limitation in people living with HIV and matched uninfected controls. *Thorax* 2018;73:431–438.
- MacDonald DM, Melzer AC, Collins G, Avihingsanon A, Crothers K, Ingraham NE, et al.; INSIGHT START Pulmonary Substudy Group. Smoking and accelerated lung function decline in HIV-positive individuals: a secondary analysis of the START pulmonary substudy. *J Acquir Immune Defic Syndr* 2018;79:e85–e92.
- Crothers K, McGinnis K, Kleerup E, Wongtrakool C, Hoo GS, Kim J, et al. HIV infection is associated with reduced pulmonary diffusing capacity. *J Acquir Immune Defic Syndr* 2013;64:271–278.

- 21 Shrestha S, Irvin MR, Grunfeld C, Arnett DK. HIV, inflammation, and calcium in atherosclerosis. *Arterioscler Thromb Vasc Biol* 2014;34:244–250.
- 22 Gibellini D, Borderi M, Clò A, Morini S, Miserocchi A, Bon I, *et al.* HIV-related mechanisms in atherosclerosis and cardiovascular diseases. *J Cardiovasc Med (Hagerstown)* 2013;14:780–790.
- 23 Gingo MR, George MP, Kessinger CJ, Lucht L, Rissler B, Weinman R, *et al.* Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. *Am J Respir Crit Care Med* 2010;182:790–796.
- 24 Polk BF, Fox R, Brookmeyer R, Kanchanaraks S, Kaslow R, Visscher B, *et al.* Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. *N Engl J Med* 1987;316:61–66.
- 25 Kirsch J, Buitrago I, Mohammed TL, Gao T, Asher CR, Novaro GM. Detection of coronary calcium during standard chest computed tomography correlates with multi-detector computed tomography coronary artery calcium score. *Int J Cardiovasc Imaging* 2012;28:1249–1256.
- 26 Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. *J Am Coll Cardiol* 1990;15:827–832.
- 27 Chandra D, Gupta A, Leader JK, Fitzpatrick M, Kingsley LA, Kleerup E, *et al.* Assessment of coronary artery calcium by chest CT compared with EKG-gated cardiac CT in the Multicenter AIDS Cohort Study. *PLoS One* 2017;12:e0176557.
- 28 Budoff MJ, Nasir K, Kinney GL, Hokanson JE, Barr RG, Steiner R, *et al.* Coronary artery and thoracic calcium on noncontrast thoracic CT scans: comparison of ungated and gated examinations in patients from the COPDGene cohort. *J Cardiovasc Comput Tomogr* 2011;5:113–118.
- 29 Azour L, Kadoch MA, Ward TJ, Eber CD, Jacobi AH. Estimation of cardiovascular risk on routine chest CT: ordinal coronary artery calcium scoring as an accurate predictor of Agatston score ranges. *J Cardiovasc Comput Tomogr* 2017;11:8–15.
- 30 Budoff MJ, Nasir K, McClelland RL, Detrano R, Wong N, Blumenthal RS, *et al.* Coronary calcium predicts events better with absolute calcium scores than age-sex-race/ethnicity percentiles: MESA (Multi-Ethnic Study of Atherosclerosis). *J Am Coll Cardiol* 2009;53:345–352.
- 31 Ferencik M, Pencina KM, Liu T, Ghemigian K, Baltrusaitis K, Massaro JM, *et al.* Coronary artery calcium distribution is an independent predictor of incident major coronary heart disease events: results from the Framingham Heart Study. *Circ Cardiovasc Imaging* 2017;10:e006592.
- 32 Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. *Arch Intern Med* 2004;164:1285–1292.
- 33 Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary calcium score and cardiovascular risk. *J Am Coll Cardiol* 2018;72:434–447.
- 34 Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, *et al.* 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. *Eur Respir J* 2017;49:1600016.
- 35 Wang Z, Gu S, Leader JK, Kundu S, Tedrow JR, Sciruba FC, *et al.* Optimal threshold in CT quantification of emphysema. *Eur Radiol* 2013;23:975–984.
- 36 Fitzpatrick ME, Nouraie M, Gingo MR, Camp D, Kessinger CJ, Sincebaugh JB, *et al.* Novel relationships of markers of monocyte activation and endothelial dysfunction with pulmonary dysfunction in HIV-infected persons. *AIDS* 2016;30:1327–1339.
- 37 Bahrami H, Budoff M, Haberlen SA, Rezaeian P, Ketlogetswe K, Tracy R, *et al.* Inflammatory markers associated with subclinical coronary artery disease: the Multicenter AIDS Cohort Study. *J Am Heart Assoc* 2016;5:e003371.
- 38 McKibben RA, Margolick JB, Grinspoon S, Li X, Palella FJ Jr, Kingsley LA, *et al.* Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection. *J Infect Dis* 2015;211:1219–1228.
- 39 Fitzpatrick ME, Singh V, Bertolet M, Lucht L, Kessinger C, Michel J, *et al.* Relationships of pulmonary function, inflammation, and T-cell activation and senescence in an HIV-infected cohort. *AIDS* 2014;28:2505–2515.
- 40 Clarenbach CF, Senn O, Sievi NA, Camen G, van Gestel AJ, Rossi VA, *et al.* Determinants of endothelial function in patients with COPD. *Eur Respir J* 2013;42:1194–1204.
- 41 Eickhoff P, Valipour A, Kiss D, Schreder M, Cekici L, Geyer K, *et al.* Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2008;178:1211–1218.
- 42 Su JB. Vascular endothelial dysfunction and pharmacological treatment. *World J Cardiol* 2015;7:719–741.
- 43 Besutti G, Raggi P, Zona S, Scaglioni R, Santoro A, Orlando G, *et al.* Independent association of subclinical coronary artery disease and emphysema in HIV-infected patients. *HIV Med* 2016;17:178–187.
- 44 Bommart S, Cournil A, Eymard-Duvernay S, Raffi F, Bouassida I, Le Moing V, *et al.*; Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) HIV CHEST Study Team. Smoking-associated morbidities on computed tomography lung cancer screens in HIV-infected smokers. *HIV Med* 2017;18:787–789.
- 45 Cotter BR. Endothelial dysfunction in HIV infection. *Curr HIV/AIDS Rep* 2006;3:126–131.
- 46 López M, San Román J, Estrada V, Vispo E, Blanco F, Soriano V. Endothelial dysfunction in HIV infection – the role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages. *AIDS Rev* 2012;14:223–230.
- 47 Solages A, Vita JA, Thornton DJ, Murray J, Heeren T, Craven DE, *et al.* Endothelial function in HIV-infected persons. *Clin Infect Dis* 2006;42:1325–1332.
- 48 Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. *Vasc Health Risk Manag* 2005;1:183–198.
- 49 Triant VA, Perez J, Regan S, Massaro JM, Meigs JB, Grinspoon SK, *et al.* Cardiovascular risk prediction functions underestimate risk in HIV infection. *Circulation* 2018;137:2203–2214.
- 50 Thompson-Paul AM, Lichtenstein KA, Armon C, Palella FJ Jr, Skarbinski J, Chmiel JS, *et al.* Cardiovascular disease risk prediction in the HIV Outpatient Study. *Clin Infect Dis* 2016;63:1508–1516.
- 51 Eckard AR, Meissner EG, Singh I, McComsey GA. Cardiovascular disease, statins, and HIV. *J Infect Dis* 2016;214(Suppl 2):S83–S92.
- 52 Longenecker CT, Eckard AR, McComsey GA. Statins to improve cardiovascular outcomes in treated HIV infection. *Curr Opin Infect Dis* 2016;29:1–9.
- 53 Morris A, Fitzpatrick M, Bertolet M, Qin S, Kingsley L, Leo N, *et al.* Use of rosuvastatin in HIV-associated chronic obstructive pulmonary disease. *AIDS* 2017;31:539–544.
- 54 Putman RK, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M, *et al.*; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators; COPDGene Investigators. Association Between Interstitial Lung Abnormalities and All-Cause Mortality. *JAMA* 2016;315:672–681.